Searched for
QILU PHARMACEUTICAL
Cipla’s US recovery, biosimilar pipeline key to future growth prospectsCipla's September-quarter earnings suffered due to a high base in its US business. The company reported sequential growth driven by its str...- Cipla sets sights on first-wave gains from rollout of Keytruda BiosimilarCipla has partnered with Qilu Pharmaceutical to commercialize a biosimilar of Keytruda, which is a major cancer treatment. The patent for t...
- Cipla Q2 net profit falls 35% to Rs 878 crore, revenue dips 2%Cipla reported a 35% year-on-year decline in second-quarter net profit to Rs 878 crore, with revenue and EBITDA also falling amid weaker No...
- Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore; revenue slips 2%Cipla reported a 35% drop in consolidated net profit for Q2FY27, which stood at Rs 878 crore. The company also experienced a 2.4% year-on-y...
- CPHI Milan: Beyond generics, how Indian pharma is rewriting its global playbookAt CPHI Milan, Indian pharma players are looking beyond traditional exports, using partnerships, licensing, CDMO, and differentiated produc...
- Lupin gets USFDA approval for Modafinil tablets to treat excessive sleepinessPharmaceutical major Lupin announced its USFDA approval for Modafinil tablets. These tablets are used to treat excessive sleepiness in adul...
- Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilarCipla said its US unit has entered an exclusive partnership with China’s Qilu Pharmaceutical to license QL2107, a biosimilar of Merck’s can...
- need2know: 10 market-moving macro triggers to watch todayA lowdown on top macro triggers that are likely to move the market on Monday
Load More